Bright Green Strengthens its Scientific Advisory Board with the Appointment of Five Additional Biotech and Pharmaceutical Leaders
Bright Green Corporation (NASDAQ: BGXX) has expanded its Scientific Advisory Board (SAB) to enhance its position as a leading federally-authorized provider of cannabis products. The board, chaired by Colin Stott, includes experts in pharmaceutical development and regulatory compliance. The SAB will guide the company during its construction phase at the agricultural complex in New Mexico, supporting Bright Green's goal to meet the demand for federally approved cannabis. This strategic expansion aims to strengthen business growth and regulatory achievements.
- Strengthened leadership through the expanded Scientific Advisory Board.
- Expertise in pharmaceutical development and regulatory compliance among SAB members.
- Focus on meeting demand for federally approved cannabis products.
- Risks associated with the construction and operational ramp-up in New Mexico.
Expansion of Bright Green’s Scientific Advisory Board supports its mission to be the premier federally-authorized provider of cannabis and derivative products
GRANTS, N.M., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ: BGXX) (“Bright Green” or “the Company”), one of the very few companies selected by the U.S. government to grow, manufacture, and sell, legally under federal and state laws, cannabis and cannabis-related products for research, pharmaceutical applications and affiliated export, today announced that it has expanded its Scientific Advisory Board (“SAB”). The SAB – comprised of a strong group of industry leaders and chaired by Colin Stott, Chief Operating Officer at Alterola Biotech, Inc. (OTC: ABTI) – will work cohesively with Bright Green’s senior management to advance the Company’s long-term business growth and position it for future success. In the near term, it will provide guidance related to ongoing construction at its agricultural complex in Grants, New Mexico, as Bright Green prepares to ramp up its operations to meet the demand for federally approved cannabis for the U.S. and international markets.
“The prestigious group of scientific and operational leaders we have assembled to sit on our Scientific Advisory Board will provide Bright Green with informed counsel in the months and years ahead,” said Terry Rafih, CEO and Executive Chairman of the Board of Bright Green. “These new appointments bring experience across technology, pharmaceutical development, GMP manufacturing, as well as early-stage research to late-stage clinical development of human therapeutics. Their collective expertise will serve us well as we expand our manufacturing facilities and will support the Company as we capitalize on commercial opportunities and achieve regulatory milestones.”
“I am delighted to be appointed Chair of Bright Green’s Scientific Advisory Board, and to be part of such a distinguished group of industry experts,” said Colin Stott, Chief Operating Officer of Alterola Biotech. “Collectively, we will guide Bright Green through the development of its facilities in New Mexico and ensure compliance with all regulatory and agency requirements to deliver high quality API material for the U.S. and international markets.”
The newly appointed members of Bright Green’s SAB are outlined below:
Colin Stott
Chairman of the Scientific Advisory Board
Colin Stott is currently Chief Operating Officer at Alterola Biotech. Prior to Alterola, he spent almost two decades at GW Pharmaceuticals, where he was a leader in Scientific Affairs and R&D Operations. He also held key research roles in other well-known companies in the U.K., including Napp Pharmaceuticals, Phytopharm, Zeneca Pharmaceuticals, Alpha Therapeutics UK and Schering-Plough Research Institute. He is also a founder of Phytotherapeutix Ltd and was Chief Operating Officer at Alinova Biosciences Ltd. He holds a Bachelor of Science degree, with Honors, and a Diploma in Industrial Studies and Medicinal and Pharmaceutical Chemistry from Loughborough University in the U.K.
Guy Webber
Scientific Advisory Board Member
Guy Webber is the founder of DMPK Services, a consultancy focused on pre-clinical Investigational New Drug applications. He holds over 25 years of drug development experience with pharmaceutical companies, as well as contract research organizers, supporting four successful new drug applications. He previously served as Group Leader, Early Drug Development at Evotec, and held scientific manager roles at Covance, Envigo, and GW Pharmaceuticals. He started his career as a Study Director and Research Scientist at Huntingdon Life Sciences and GSK, respectively. He holds a Bachelor of Science degree, with Honors, in Chemistry, and a Master of Science in Medicinal Chemistry and Drug Metabolism from Loughborough University in the U.K.
Dominic Schiller
Scientific Advisory Board Member
Dominic Schiller is a Chartered and European Patent Attorney with over 30 years of experience, largely in the pharmaceutical, botanical and nutraceutical industries. He is the founder and CEO of Equipped 4 Holdings Limited, the parent company of Equipped 4 (IP) Limited, an Intellectual Property law practice specializing in building patent portfolios for biotech companies, most notably GW Pharmaceuticals and Compass Pathways. Mr. Schiller successfully secured some of the earliest and most prominent cannabinoid-related patents for GW Pharma, helping them establish an IP portfolio comprising claims directed to plants, plant extracts, extraction technology, pharmaceutical formulations, drug delivery and the therapeutic uses of cannabinoids, as well as plant variety rights. He was also the patent attorney behind Compass Pathways, a mental health care company. He holds a combined honors degree in Biochemistry and Genetics from Leeds University and earned his MBA from Liverpool University.
Tamás Bíró
Scientific Advisory Board Member
Tamás Bíró, MD, PhD, DSc and Professor of Physiology, Neurobiology, and Immunology, is a renowned academic and researcher with over 20 years of experience in academia. His research focused largely on the regulatory role of the endocannabinoid system and the closely related family of the TRP ion channels in the formation and establishment of the complex barrier of the human skin. Multiple projects of his Labs aimed at exploiting the potential of numerous synthetic and plant-derived molecules, targeting the endocannabinoid system and certain TRP channels, in the therapeutic management of various diseases. He received his medical degree from the University of Debrecen and spent two years as a Fogarty fellow at the National Cancer Institute (NIH). He received his PhD in physiology and neurobiology at the University of Debrecen.
Brian Thomas
Scientific Advisory Board Member
Brian Thomas, PhD, is a former medical researcher with over 28 years of experience as a Principal Investigator on National Institute on Drug Abuse (NIDA) research contracts at Research Triangle Institute (RTI) and the University of Mississippi. In these roles, he coordinated the preparation and analysis of research drugs and substance abuse treatment medications at RTI, including a variety of novel cannabinoid drug substances and formulations, and over 35 million tobacco cigarettes of varying nicotine content for the United States Food and Drug Administration (FDA) to support clinical trials of reduced nicotine exposure tobacco products. In 2019, he joined Canopy Growth Corporation as Senior Director, Analytical Chemistry, Discovery Sciences, and Pharmaceutics, where he had management oversight of drug substance and product testing to support preclinical and clinical studies in accordance with regulatory guidance. He then joined The Cronos Group to serve as the Director of Analytical Sciences. Currently, he provides pharmaceutical consulting services as Empirical Pharmaceutical Services, LLC.
About Bright Green
Bright Green is one of the very few companies selected by the US government to grow, manufacture, and sell, legally under federal and state laws, cannabis and cannabis-related products for research, pharmaceutical applications and affiliated export. Our conditional approval based on already agreed terms from the U.S. Drug Enforcement Administration gives us the opportunity to advance our vision of improving quality of life through the opportunities presented by cannabis-derived therapies. To learn more, visit www.brightgreen.us.
Cautionary Note Regarding Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management as of such date. Words such as “expect,” “anticipate,” “should,” “believe,” “hope,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “might,” “could,” “intend,” “shall” and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission (the “SEC”) on March 29, 2022 and declared effective May 13, 2022, and in the Company’s Quarterly Report on Form 10-Q/A filed with the SEC on August 19, 2022, as well as other documents that may be filed by the Company from time to time with the SEC. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause its views to change. The Company undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release. Additional information regarding these and other factors that could affect the Company’s results is included in the Company’s SEC filings, which may be obtained by visiting the SEC's website at www.sec.gov.
Bright Green Media Contact
BrightGreen@edelman.com
Bright Green Investor Relations Contact
BrightGreenIR@edelman.com
FAQ
What is the role of Bright Green's expanded Scientific Advisory Board?
Who is the chairman of Bright Green's Scientific Advisory Board?
How does the expansion of the Scientific Advisory Board impact Bright Green's operations?
What challenges does Bright Green face with its construction projects?
